Safi Biotherapeutics Secures $4.7 Million To Advance Manufactured Red Blood Cells Toward First Clinical Trial
By Elizabeth Urbanek, Executive Editor
Safi Biotherapeutics has received a $4.7 million funding extension from the U.S. Department of War to advance its stem cell-derived manufactured red blood cells (mRBCs) toward their first clinical trial, adding funding for the final development work ahead of a planned 2027 Investigational New Drug (IND) submission.
The Nov. 3 announcement says the award, provided through the Department of War's Defense Health Program Combat Casualty Care portfolio and the Medical Technology Enterprise Consortium (MTEC), will support activities needed to advance the company's mRBC product toward clinical testing for acute blood loss.
The latest award brings Safi's total non-dilutive government funding to more than $27 million. The company is developing manufactured human red blood cells for potential civilian and military transfusion applications.
Safi reports that its manufacturing process can produce more than one full transfusable unit in a single 10-liter bioreactor. The company identifies production at clinically meaningful scale as a longstanding challenge for manufactured blood products.
The funding will also support continued development of a readily transfusable, cryopreserved mRBC formulation.
Manufacturing Progress Brings Clinical Supply Considerations Into Focus
The move toward clinical testing follows a January 2026 manufacturing milestone. Safi and ARMI | BioFabUSA announced the successful technical transfer of the company's 10-liter mRBC production system, describing the transfer as a step toward GMP manufacturing at clinically meaningful scale.
That work is important because manufacturing capacity alone does not establish clinical supply readiness. Sponsors must also consider whether production processes can deliver consistent product, meet applicable quality requirements, and support the timelines and quantities required for a clinical study.
For manufactured red blood cells, those considerations extend beyond conventional pharmaceutical supply planning. The product is a cellular therapy intended for transfusion, making manufacturing controls, product quality, storage conditions, and handling important elements of the development program.
The company's January announcement identified the technical transfer as a milestone toward regulatory manufacturing requirements. Its November funding announcement moves the focus to completing the work needed for an IND submission and first-in-human testing.
What This Means For Clinical Supply
The development raises questions that clinical supply teams will need to address as manufactured blood products move into human studies.
Storage and product stability are particularly relevant. Safi's development pipeline includes refrigerated, cryopreserved, and freeze-dried mRBC formulations. Each approach could introduce different requirements for product handling, storage, transportation, and inventory management.
The company says it is continuing development of a readily transfusable, cryopreserved formulation. However, the announcement does not provide validated shelf-life specifications, transportation conditions, or distribution requirements for the clinical product. Those details will matter as the company advances its development program.
Manufacturing capacity will also need to translate into reliable clinical supply. Producing more than one transfusable unit in a 10-liter bioreactor is a meaningful manufacturing milestone, but clinical deployment will require additional evidence of product consistency, quality, and reproducibility.
For clinical supply professionals, the transition illustrates why manufacturing scale-up, quality planning, and logistics considerations need to develop together. A product intended for transfusion must be available when and where it is needed, under conditions that preserve its required quality.
The Supply Question
How will sponsors maintain product quality through manufacturing, storage and distribution as mRBCs enter clinical trials?
Related Clinical Supply Leader Editorials:
- How Clinical Supply Is Shaping The Next Generation Of Cell And Gene Therapies
- The Biggest Early-Stage Clinical Supply Mistake? Building Too Much, Too Soon.
About The Author
Elizabeth Urbanek is the executive editor of Clinical Supply Leader, where she works with clinical trial supply and logistics professionals across pharma and biotech to bring real-world perspectives, operational challenges, trends, scientific insights, and regulatory strategy to the field.
Before joining life sciences media, Elizabeth spent more than 15 years in broadcast, digital, and live-event storytelling, helping highly technical teams communicate complex ideas with clarity and impact. She brings that same approach to clinical supply, creating editorial space for experts to share what is happening across clinical trial operations.
Elizabeth is passionate about connecting people and ideas, identifying emerging themes, and showcasing work that can move the clinical supply field forward.